AnaptysBio, Inc.

It out-grows 97% of companies worldwide.

Revenue grew 84%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 52%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 33%/yr over five years.10/10

Revenue grew 84%/yr over the last 3 years; forecasts see it cooling to 52%/yr.

Earnings are set to grow in step with sales (EPS about 50%/yr vs revenue 52%/yr). One year dips: EPS falls 54% next year.

None flagged.

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

Magnificent long-term results. Long-term holders have seen +256% over three years and +144% over five, ahead of 80% of the market.

Strong recent results. The stock is outperforming so far this year (+41%).

It's up 115% over the past year, but 37% below its 52-week high. That is a touch ahead of the market.

The stock is underperforming over the past month (-19%) and over three months (-30%).

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the stock is underperforming over the past month and over three months.